Regulatory FDA hands another rejection to Replimune’s melanoma therapy PharmaphorumReplimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.RegulatoryOncologyRead full story pharminent April 13, 2026 (Last updated: April 13, 2026) Pharmaphorum Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses. RegulatoryOncologyRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Bayer wins MHRA approval for Kerendia in heart failureNext: FDA issues complete response letter to Replimune’s RP1 for melanoma Related Stories Regulatory FDA approves MSD’s Keytruda combinations for MIBC pharminent July 13, 2026 Regulatory FDA freezes CRL trove as ‘radical transparency’ push hits speedbump pharminent July 9, 2026 Regulatory UK first in Europe to clear Boehringer’s IPF drug Jascayd pharminent July 9, 2026
